These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 17658909)
1. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Booth BA; Vidal Denham L; Bouhanik S; Jacob JT; Hill JM Drugs Aging; 2007; 24(7):581-602. PubMed ID: 17658909 [TBL] [Abstract][Full Text] [Related]
2. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Myles ME; Neumann DM; Hill JM Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884 [TBL] [Abstract][Full Text] [Related]
3. Protein conjugates and fusion proteins as ocular therapeutics. Mehta SC; Kelley RF; Tesar DB Drug Discov Today; 2019 Aug; 24(8):1440-1445. PubMed ID: 31202674 [TBL] [Abstract][Full Text] [Related]
5. Advances in ocular drug delivery: emphasis on the posterior segment. Kang-Mieler JJ; Osswald CR; Mieler WF Expert Opin Drug Deliv; 2014 Oct; 11(10):1647-60. PubMed ID: 24975820 [TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye. Bisht R; Jaiswal JK; Rupenthal ID Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in intraocular drug delivery systems. Yasukawa T; Tabata Y; Kimura H; Ogura Y Recent Pat Drug Deliv Formul; 2011 Jan; 5(1):1-10. PubMed ID: 21143129 [TBL] [Abstract][Full Text] [Related]
8. Drug delivery to the posterior segment of the eye. Fischer N; Narayanan R; Loewenstein A; Kuppermann BD Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325 [TBL] [Abstract][Full Text] [Related]
9. Novel drug delivery systems for retinal diseases. A review. Lee SS; Robinson MR Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933 [TBL] [Abstract][Full Text] [Related]
10. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye. Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392 [TBL] [Abstract][Full Text] [Related]
11. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Del Amo EM; Urtti A Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911 [TBL] [Abstract][Full Text] [Related]
12. Advance of the application of nano-controlled release system in ophthalmic drug delivery. Wang X; Wang S; Zhang Y Drug Deliv; 2016 Oct; 23(8):2897-2901. PubMed ID: 26635087 [TBL] [Abstract][Full Text] [Related]
13. Application of encapsulated cell technology for retinal degenerative diseases. Tao W Expert Opin Biol Ther; 2006 Jul; 6(7):717-26. PubMed ID: 16805711 [TBL] [Abstract][Full Text] [Related]
14. Ophthalmic drug discovery. Clark AF; Yorio T Nat Rev Drug Discov; 2003 Jun; 2(6):448-59. PubMed ID: 12776220 [TBL] [Abstract][Full Text] [Related]
15. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies. Alshaikh RA; Waeber C; Ryan KB Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559 [TBL] [Abstract][Full Text] [Related]
16. 2nd Ophthalmic Drug Development and Delivery Summit. Marra M; Gukasyan HJ; Raghava S; Kompella UB Expert Opin Drug Deliv; 2007 Jan; 4(1):77-85. PubMed ID: 17184164 [TBL] [Abstract][Full Text] [Related]